# Matthew D. Galsky

Source: https://onco.cc/people/matthew-galsky/  
OnCo record `matthew-galsky` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led trials that brought immunotherapy into bladder cancer and tested skipping cystectomy in responders.

## Summary

Matthew D. Galsky is Director of Genitourinary Medical Oncology and Co-Director of the Center of Excellence for Bladder Cancer at The Mount Sinai Hospital and Tisch Cancer Institute. He is a genitourinary oncologist known for leading trials that brought immunotherapy into bladder cancer, including IMvigor130, and for testing whether responders to chemo-immunotherapy can skip cystectomy. His selected paper reports atezolizumab with or without chemotherapy in metastatic urothelial cancer in IMvigor130. He continues to study bladder preservation in muscle-invasive disease and immunotherapy with atezolizumab and nivolumab.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Genitourinary Medical Oncology; Co-Director, Center of Excellence for Bladder Cancer
- Specialisms: Bladder cancer; Immunotherapy; Bladder preservation

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Galsky%20MD%5BAuthor%5D

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [The Mount Sinai Hospital / Tisch Cancer Institute](https://onco.cc/institutions/mount-sinai/)
- key papers: [NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer](https://onco.cc/key-papers/paper-niagara-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/matthew-galsky.json